Evidence map›Paper›PMID 38830862›Full record

ArticleTranslational psychiatry2024

Analysis of human neuronal cells carrying ASTN2 deletion associated with psychiatric disorders.

Yu Hayashi, Hiroki Okumura, Yuko Arioka, Itaru Kushima, Daisuke Mori, Tzuyao Lo, Gantsooj Otgonbayar, Hidekazu Kato, Yoshihiro Nawa, Hiroki Kimura and 2 more

Abstract read
In one paragraph

Article in Translational psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Observational
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yu Hayashi *Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroki Okumura *Department of Hospital Pharmacy, Nagoya University Hospital, Nagoya, Japan.
Yuko AriokaPathophysiology of Mental Disorders, Nagoya University Graduate School of Medicine, Nagoya, Japan. ariokay@med.nagoya-u.ac.jp.ORCID 0000-0002-1792-8812
Itaru KushimaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0002-0018-5178
Daisuke MoriPathophysiology of Mental Disorders, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0002-9072-2546
Tzuyao LoDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Gantsooj OtgonbayarDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hidekazu KatoDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0001-9995-504X
Yoshihiro NawaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0003-3164-2519
Hiroki KimuraDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Branko AleksicDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0001-8982-4580
Norio OzakiPathophysiology of Mental Disorders, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0002-7360-4898

Funding

Japan Agency for Medical Research and Development (AMED) JP19ak0101113Japan Agency for Medical Research and Development (AMED) JP19dm0207075Japan Agency for Medical Research and Development (AMED) JP21dk0307103Japan Agency for Medical Research and Development (AMED) JP21wm0425007Japan Agency for Medical Research and Development (AMED) JP22ek0109601Japan Agency for Medical Research and Development (AMED) JP22tm0424222
6 · The paper itself

Abstract

Recent genetic studies have found common genomic risk variants among psychiatric disorders, strongly suggesting the overlaps in their molecular and cellular mechanism. Our research group identified the variant in ASTN2 as one of the candidate risk factors across these psychiatric disorders by whole-genome copy number variation analysis. However, the alterations in the human neuronal cells resulting from ASTN2 variants identified in patients remain unknown. To address this, we used patient-derived and genome-edited iPS cells with ASTN2 deletion; cells were further differentiated into neuronal cells. A comprehensive gene expression analysis using genome-edited iPS cells with variants on both alleles revealed that the expression level of ZNF558, a gene specifically expressed in human forebrain neural progenitor cells, was greatly reduced in ASTN2-deleted neuronal cells. Furthermore, the expression of the mitophagy-related gene SPATA18, which is repressed by ZNF558, and mitophagy activity were increased in ASTN2-deleted neuronal cells. These phenotypes were also detected in neuronal cells differentiated from patient-derived iPS cells with heterozygous ASTN2 deletion. Our results suggest that ASTN2 deletion is related to the common pathogenic mechanism of psychiatric disorders by regulating mitophagy via ZNF558.

Indexed as

GlycoproteinsInduced Pluripotent Stem CellsMental DisordersNerve Tissue ProteinsNeuronsCell DifferentiationDNA Copy Number VariationsGene DeletionHumansNeural Stem CellsTranscription FactorsASTN2 protein, humanGlycoproteinsNerve Tissue ProteinsTranscription Factors

Identifiers

PMID38830862
PMCPMC11148150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.